FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Healthy
Interventions
DIETARY_SUPPLEMENT

Flaxseed Lignans

We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.

Trial Locations (1)

98109

FHCRC, Seattle

All Listed Sponsors
collaborator

Texas A&M University

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01619020 - FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health | Biotech Hunter | Biotech Hunter